Table 1. Clinicopathological characteristics of the primary cohort (n = 100) and validation cohort (n = 31).
| Primary cohort (n, %) | Validation cohort (n, %) | |
|---|---|---|
| Age | ||
| < 50 | 53 (53) | 15 (48) |
| > = 50 | 47 (47) | 16 (52) |
| Ethnicity | ||
| Chinese | 65 (65) | 14 (45) |
| Malay & others | 35 (35) | 17 (55) |
| Tumour grade | ||
| 1 | 10 (10) | 2 (7) |
| 2 | 49 (49) | 10 (32) |
| 3 | 41 (41) | 19 (61) |
| T4 stage | ||
| No | 26 (26) | 19 (61) |
| Yes | 74 (74) | 12 (39) |
| Metastasis | ||
| No | 69 (69) | 22 (71) |
| Yes | 31 (31) | 9 (29) |
| Treatment arm | ||
| A-T-A-T-A-T | 49 (49) | NA |
| T-A-T-A-T-A | 51 (51) | NA |
| 25% tumour reduction at cycle 1 | ||
| < 25% | 43 (43) | 15 (48) |
| ≥ 25% | 57 (57) | 16 (52) |
| Pathological lymph node involvement a | ||
| No | 31 (41) | 7 (24) |
| Yes | 44 (59) | 22 (76) |
a
75 and 29 patients in the primary and validation cohort underwent surgery respectively; NA: not applicable.